Compare PPT & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PPT | RXST |
|---|---|---|
| Founded | 1988 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 343.1M | 366.3M |
| IPO Year | N/A | 2021 |
| Metric | PPT | RXST |
|---|---|---|
| Price | $3.63 | $8.04 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $11.40 |
| AVG Volume (30 Days) | 156.1K | ★ 1.1M |
| Earning Date | 01-01-0001 | 02-25-2026 |
| Dividend Yield | ★ 8.84% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $142,085,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.75 |
| 52 Week Low | $3.25 | $6.32 |
| 52 Week High | $3.72 | $32.25 |
| Indicator | PPT | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 51.17 | 36.31 |
| Support Level | $3.58 | $7.65 |
| Resistance Level | $3.66 | $8.51 |
| Average True Range (ATR) | 0.03 | 0.52 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 46.15 | 19.91 |
Putnam Premier Income Trust is a closed-end fixed income fund that prominently invests in U.S. government, agency, high-yield, and international fixed income securities. The fund aims to provide high current income while preserving capital by diversifying across multiple bond markets beyond traditional benchmarks. Its portfolio includes various sectors such as investment-grade and high-yield corporate bonds, mortgage-backed securities, bank loans, and emerging market debt. Revenue for the trust is generated through interest income and capital gains from its investments in a fixed fund, which operates on the New York Stock Exchange and focuses on managing a diverse range of fixed-income assets across various countries.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.